Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold

Pembrolizumab monotherapy has been demonstrated as a first-line therapy for non-small-cell lung cancer (NSCLC) patients with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of ≥50%; however, the clinical efficacy is limited by the unreasonable threshold of the TPS. A recent study pu...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Cell Commun Signal
Huvudupphovsmän: Xu, Zhijie, Wang, Xiang, Chen, Xi, Zeng, Shuangshuang, Gong, Zhicheng, Yan, Yuanliang
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Netherlands 2020
Ämnen:
Bits and Bytes
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7176773/
https://ncbi.nlm.nih.gov/pubmed/31933275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12079-020-00547-6
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk